Lead Product(s): Human fibrinogen,Thrombin
Therapeutic Area: Hematology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 10, 2020
In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.